Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of our first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. Early clinical data suggest imetelstat may have disease-modifying activity through the suppression of malignant progenitor cell clone proliferation, which allows potential recovery of normal hematopoiesis. Telomerase is an enzyme that enables cancer cells, including malignant progenitor cells, to maintain telomere length, which provides them with the capacity for limitless, uncontrolled proliferation. Using Geronâs proprietary nucleic acid chemistry, imetelstat was designed as an oligonucleotide that targets and binds with high affinity to the active site of telomerase, thereby directly inhibiting telomerase activity and impeding malignant cell proliferation. Ongoing clinical studies of imetelstat consist of IMergeâ˘, a Phase 2/3 trial in lower risk myelodysplastic syndromes (MDS) and IMbarkâ˘, a Phase 2 trial in Intermediate-2 or High-risk myelofibrosis. Source
No articles found.
MediWound is a fully integrated biopharmaceutical company focused on developing, m...
MediWound is a fully integrated biopharmaceutic...
Lipocine Inc. is a clinical-stage biopharmaceutical company focused on metabolic a...
Lipocine Inc. is a clinical-stage biopharmaceut...
Organovo is a biotech platform company that has developed a leadership position wi...
Organovo is a biotech platform company that has...
Vanda is developing important new medicines to improve the lives of patients. We u...
Vanda is developing important new medicines to ...
Crinetics is a clinical stage pharmaceutical company focused on the discovery, dev...
Crinetics is a clinical stage pharmaceutical co...
Tiziana Life Sciences is a dual-listed (NASDAQ:TLSA, AIM:TILS) clinical stage biot...
Tiziana Life Sciences is a dual-listed (NASDAQ:...
Precipio has built a platform designed to eradicate the problem of misdiagnosis by...
Precipio has built a platform designed to eradi...
Join the National Investor Network and get the latest information with your interests in mind.